CD19 and hematologic disorder: Based on this, Zhang et al. [111] prepared a NCTD-encapsulated liposome modified with a murine anti-human CD19 monoclonal antibody 2E8 (2E8-NCTD-liposomes) by using post-incorporation technology, with average size of 118.32 nm and average EE of 46.51%, which can specifically target CD19+ leukemia cells for the treatment of B lineage hematologic malignancies.